NCT06204640View on ClinicalTrials.gov

SPironolactONe for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

580

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2029

Conditions

Atrial Fibrillation Recurrent

Interventions

DRUG

Spironolactone

Spironolactone will be start at 25 mg per day initially then titrated to a maximum of 50 mg per day in the absence of contraindication at the 1-month study visit.

All Listed Sponsors

lead

University Hospital, Caen

OTHER